Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Lazaro Gamio / Axios

Drug companies are racing to get the FDA's green light for immunotherapies to treat kids with peanut allergies — a breakthrough that might actually reduce their allergies, not just treat an allergic attack when it happens. They're testing everything from oral medicines to skin patches to vaccines and nasal sprays, with some companies hoping their products will reach the market by 2019.

Why it matters: Roughly 2% of all American children have a peanut allergy — which is one of the most dangerous food allergies — and alleviating reactions could save lives. Peanut allergy therapies also have drug companies seeing dollar signs, with a potential global market of up to $8 billion.

"If you had told me 40 years ago that AIDS would be a treatable disease and we would have [no FDA-approved drugs] for food allergies, I would have totally laughed at you. But here we are."
— James Baker Jr., CEO of consumer advocacy group Food Allergy and Research and Education

How it works: Immunotherapies aim to desensitize children's immune systems so their allergic reactions are not as severe.

Where it stands: There are almost 40 peanut allergy studies underway and listed on clinicaltrials.gov, and nearly 40 others completed recently.

"This is clearly an unmet need," says Gerald Nepom, director of Immune Tolerance Network, a mostly NIH-funded entity. The only current available remedy for patients is to avoid peanuts and carry an epinephrine shot at all times.

What to watch: The two therapies likely to seek regulatory approval first are a skin patch called Viaskin Peanut, by the French company DBV Technologies, and a pill called AR101, by California-based Aimmune Therapeutics.

Both are designed to deliver small amounts of peanut protein to "train the immune system to see peanut protein in a harmless sort of way," Nepom says.

  • DBV's small bandage-like patch would be for 4- to 11-year-old children. Hugh Sampson, DBV's chief scientific officer, tells Axios the patches work by transmitting the peanut protein through the skin to so-called Langerhans cells that then transport it to lymph nodes in order to reach the immune system.
  • Late-stage trials for the patch recently found it missed one of the benchmarks for the level of efficacy normally needed for FDA approval, although earlier trials had shown promise. Sampson says they'll still submit their application.
  • Aimmune's pill is currently being tested in patients 4 to 55 years old who take a pill daily for about 20 weeks with increasing dosages of peanut protein. Their application will likely go to the FDA in the first quarter of 2018.

In comparing the two trials so far, Baker says the skin patch showed lower efficacy but few side effects, while the pill had a higher rate of efficacy but wasn't tolerated as well by the patients. He says while it may take time to get either of these to the market, either would be welcomed as "we have nothing out there right now."

Early-stage trials: There are also dozens of other therapies in earlier testing stages.

The market: If approved, the launch prices of the products will be closely watched, given the outcry over egregious drug industry pricing practices. Aimmune believes its market will yield $1 billion in sales in the U.S., but some venture capital firms think the overall market will be even larger, since peanut allergies are often lifelong conditions.

Vamil Divan, a pharmaceutical industry analyst at Credit Suisse, says Aimmune's pill could command a price of more than $5,000 during the six-month ramp-up stage and then $400 per month "for maintenance." He estimates Aimmune could be collecting $1.3 billion of revenue and almost $600 million of profit by 2023.

The big questions:

  • How health insurers will cover the treatments?
  • Will parents of kids with peanut allergies pay a lot out of their own pockets when they buy the treatments?
  • How long kids will stay on the therapies before consuming small quantities of peanuts on their own?

Editor's note: We updated the quote in the third graph to clarify that Baker was talking about FDA-approved drugs.

Go deeper

Ina Fried, author of Login
2 hours ago - Technology

Intel CEO sees making own chips as a matter of national security

Pat Gelsinger. Photo: Axios on HBO

Intel CEO Pat Gelsinger is putting the pressure on the U.S. government to help subsidize chip manufacturing, insisting the current reliance on plants in Taiwan and Korea as "geopolitically unstable."

Why it matters: There is bipartisan support for funding the domestic semiconductor industry, but Congress has yet to sign the check. The Senate has passed the CHIPS Act that includes $52 billion in semiconductor investment, but it has yet to pass the House.

Updated 2 hours ago - World

17 U.S. and Canadian missionaries kidnapped in Haiti

Haitian soldiers guard the public prosecutor's office in Port-au-Prince this month. Photo: Richard Pierrin/AFP via Getty Images

Children are among a group of 17 missionaries kidnapped in Port-au-Prince, Haiti, per a statement from Christian Aid Ministries Sunday.

The latest: "The group of 16 U.S citizens and one Canadian citizen includes five men, seven women, and five children," the Ohio-based group said. Haitian police inspector Frantz Champagne on Sunday identified the 400 Mawozo gang as the group responsible, in a statement to AP.

Ina Fried, author of Login
4 hours ago - Technology

Intel CEO wants to compete against Apple

Intel CEO Pat Gelsinger hasn't given up on the idea of the Mac once again using Intel chips, but he acknowledges it will probably be years before he gets that chance.

  • In the meantime, he is focused on powering Windows machines that give Apple CEO Tim Cook a run for his money.

Why it matters: In getting pushed out of the Mac, Intel not only lost a customer but picked up a new rival.